Pancreatic enzyme therapy in cystic fibrosis

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

The author has been an ad hoc independent advisor to several companies marketing pancreatic enzymes during the past 30 years. Between 1997 and 1999, JA Dodge was a paid consultant to Scandipharm, an American company who were taken over by Axcan (Canada), at which point his consultancy was terminated. The author has no financial interests in any pharmaceutical company. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.